Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

By K. Chan, I. Espinosa, M. Chao, D. Wong, L. Ailles, M. Diehn, H. Gill, J. Presti, Howard Y. Chang, M. van de Rijn and 2 more. Proceedings of the National Academy of Sciences of the United States of America, 2009

653 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Surgery

View Paper: https://www.semanticscholar.org/paper/7ca71fcbc3a9ed3be014f450840f28aa95a8501b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Irving L. Weissman
2. R. Majeti
3. M. Chao
4. Hans Lassmann
5. M. Clarke
6. Siddhartha Jaiswal

In Molecular Biology

1. M. Clarke
2. Irving L. Weissman
3. Piero Dalerba
4. R. Majeti
5. Hans Lassmann
6. T. Schatton
7. M. Frank
8. Siddhartha Jaiswal

In Surgery

1. William Y. Kim

Citations in the corpus

• Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy (2014, neutral): “The invasive/ metastatic phenotype was associated with expression of ‘‘mesenchymal’’ and bladder cancer stem cell (Chan et al., 2009) biomarkers, and the tumors were enriched with sarcomatoid and squamous features (Blaveri et al.”
• The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors (2012, background): “We previously demonstrated that blockade of CD47-mediated SIRPα signaling using targeted monoclonal antibodies (mAbs) induced the phagocytosis of leukemia, lymphoma, and bladder cancer cells by human and mouse macrophages (5, 16, 17, 26).”
• iNOS promotes CD24+CD133+ liver cancer stem cell phenotype through a TACE/ADAM17-dependent Notch signaling pathway (2018, background): “Links have been made between iNOS and NO in promoting the stem cell compartment during neoplastic transformation in colon cancer and gliomas (17, 42).”
• MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. (2009, background): “Beyond this, expression of CD47 on haematopoietic stem cells, leukaemia cells or other tumour cells leads to prevention of phagocytosis (Blazar et al., 2001; Chan et al., 2009; Jaiswal et al., 2009; Majeti et al., 2009).”
• The therapeutic promise of the cancer stem cell concept. (2010, background): “The Journal of Clinical Investigation http://www.jci.org Volume 120 Number 1 January 2010 47 In human bladder cancer, CSCs were recently identified as Lin–CD44+CK5+CK20– (29).”
• Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology (2014, background): “In keeping with these findings, we found that a previously published bladder tumor initiating cell (TIC) signature (22) was enriched in the basal-like subtype by both hierarchical clustering (P = 2 × 10, χ(2) test) (SI Appendix, Fig.”
• Identification of miR-34a as a potent inhibitor of prostate cancer progenitor cells and metastasis by directly repressing CD44 (2011, neutral): “(iv) We carried out the same procedure as in (iii) but with more animals (n = 10 for each group) and more injections (15).”
• Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma (2010, neutral): “, 2009), bladder cancer (Chan et al., 2009), and now NHL, leading us to speculate that CD47 targeting will be effective against a wide range of human cancers.”